Home » Newsletters » BioWorld Science

BioWorld Science

May 14, 2020

View Archived Issues

Copper escort alleviates Menkes disease

Immunity-related pathways contribute to the genetic burden of asthma pathology, new GWAS shows

Phase I data presented for LC51-0255

TBR-760 results in complete arrested tumor growth in mouse model of NFPA

Discovery of potent BACE1 inhibitor, AM-6494

First patient dosed in phase I/II study of TJD5 in China

Sunovion discontinues development of dasotraline

New androgen receptor antagonists described by ESSA Pharma

Enrollment of first patient in phase III study of viltolarsen in boys with DMD

Insilico Medicine Hong Kong discovers DDR1 inhibitors

Ascletis receives IND approval in China for clinical development of ASC-41 in NASH

Nurix Therapeutics patents Bruton tyrosine kinase-degrading compounds

ViiV Healthcare discovers new HIV-1 Capsid protein p24 assembly inhibitors

New adenosine A2A and A2B receptors disclosed by Merck KGaA

miRNA-126-5p circulating levels are decreased in severe sepsis

Improved therapeutic index could reduce opioid toxicity

Blueprint Medicines' BLU-847 shows activity against wild-type and mutant tyrosine kinase receptors

Immunic receives approval to begin phase II study of IMU-838 for COVID-19

SHISA4 expression proven useful to monitor nintedanib therapy in patients with IPF

Merck & Co. reports phase II data on MK-6482 for VHL disease-associated ccRCC

Vyriad opens phase II trial of Voyager-V1 in combination with cemiplimab for cancer

Viela reports interim phase Ib data on VIB-7734 in cutaneous lupus erythematosus

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...